There are 2789 resources available
831MO - Geptanolimab in Chinese patients with relapsed or refractory primary mediastinal large B-cell lymphoma: Results from a multicenter, open-label, single-arm phase II trial
Presenter: Yuan-Kai Shi
Session: Mini oral session - Haematological malignancies
Resources:
Abstract
Slides
Webcast
832MO - Immune microenvironment in classical Hodgkin lymphoma: Composition and dynamics in patients with relapsed/refractory disease
Presenter: Liudmila Fedorova
Session: Mini oral session - Haematological malignancies
Resources:
Abstract
Slides
Webcast
4MO - Preclinical evaluation of novel CDK4/6 inhibitor GLR2007 in breast and lung cancer models
Presenter: Lei Yin
Session: Mini oral session - Basic science
Resources:
Abstract
Slides
Webcast
5MO - CDK4/6 blockade is as effective as immune-checkpoint inhibition in tumor growth control of Mlh1-/- and Msh2loxP/loxP villin-Cre mice
Presenter: Inken Salewski
Session: Mini oral session - Basic science
Resources:
Abstract
Slides
Webcast
6MO - PCSK9 inhibitor evolocumab reduces cardiotoxicity and inflammation induced by doxorubicin-trastuzumab sequential treatment through MyD88/NF-kB/mTORC1 pathways
Presenter: Vincenzo Quagliariello
Session: Mini oral session - Basic science
Resources:
Abstract
Slides
Webcast
7MO - Effect of anti-CTLA-4 immunotherapy on lymphocyte subset and activation profiles and clonal composition on the B16F0 mouse melanoma model
Presenter: Diana Yuzhakova
Session: Mini oral session - Basic science
Resources:
Abstract
Slides
Webcast
1801MO - Neutrophils are associated with resistance to anti-PD-1 monotherapy in mismatch repair-deficient tumors
Presenter: Laetitia Nebot
Session: Mini oral session - Basic science
Resources:
Abstract
Slides
Webcast
1802MO - Influence of preoperative chemoradiation on tumor-infiltrating lymphocytes in locally advanced rectal cancer: The STAR-01 cohort
Presenter: Letizia Gnetti
Session: Mini oral session - Basic science
Resources:
Abstract
Slides
Webcast
723MO - Tisotumab vedotin (TV) + carboplatin (Carbo) in first-line (1L) or + pembrolizumab (Pembro) in previously treated (2L/3L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT-Cx8/GOG-3024/innovaTV 205 study
Presenter: Ignace Vergote
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
724MO - Balstilimab (anti-PD-1) in combination with zalifrelimab (anti-CTLA-4): Final results from a phase II study in patients (pts) with recurrent/metastatic (R/M) cervical cancer (CC)
Presenter: David O'Malley
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast